Ketotifen

H1 antihistamine / mast cell stabiliser · also known as Zaditen, Zaditor

H1 antihistamine with additional mast cell stabilising activity; oral formulations are approved outside the US but not by the FDA.

How it relates to mast cells: Mast cell disease
Types of studies cited: Randomised controlled trial
Approved in the US for: itchy eyes from allergen exposure
Randomised trials in: urticaria pigmentosa, paediatric mastocytosis

What this relationship means: Studied in patients with a different mast cell disease, usually systemic mastocytosis. Those disorders have diagnostic criteria and disease biology that differ from MCAS, so a result there does not establish an MCAS outcome. A 2025 practical-management review places this at step 5 of the sequence it describes — described for patients not controlled on high-dose second-generation H1 antihistamines. That is what the review reports, not a recommendation from this site.

Mechanism of action

Ketotifen acts at the histamine H1 receptor as an antagonist, and is additionally described in the mast cell stabiliser literature as inhibiting mediator release from mast cells. It is one of several compounds developed for another indication whose stabilising activity was identified subsequently, and reviews of the class group it with drugs whose stabilising mechanism is less fully characterised than their primary receptor action.

Because it carries both activities, ketotifen appears in treatment discussions as a single agent covering two steps that would otherwise require two drugs.

Approved elsewhere — off-label rationale

Oral ketotifen is approved as an antihistamine in Canada, the UK, and parts of Europe and Asia, where it has been marketed for decades. In the US only the ophthalmic form is available, sold over the counter for allergic conjunctivitis; systemic use requires a compounding pharmacy. Entries here describe the oral formulation, so a US reader should not assume the over-the-counter eye drops are the same intervention.

Sources

A double-blind cross-over study of the effect of ketotifen in urticaria pigmentosa Peer-reviewed study 1983 PMID 6341102 · link checked 22 Aug 2026
A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis Peer-reviewed study 1989 PMID 2654254 · link checked 22 Aug 2026
Ketotifen fumarate ophthalmic solution US over-the-counter Drug Facts label Drug label · link checked 21 Aug 2026
Mast cell stabilisers Review article 2016 PMID 26130122 · link checked 20 Aug 2026
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management Review article 2019 PMID 30961835 · link checked 20 Aug 2026

What this evidence cannot establish

There is no primary report of ketotifen outcomes in MCAS patients cited here, and this entry previously claimed one. What exists is two small double-blind crossover studies from the 1980s, in urticaria pigmentosa and in paediatric mastocytosis — randomised, but tiny, old, and in a different disease. Ketotifen is also usually added to an existing regimen rather than used alone, so even uncontrolled reports cannot attribute anything to it specifically.

What this page does not say

No dosing, and no claim that this works. The entry describes a published mechanism, the cited study types, and what those studies cannot establish — nothing further. Why the site is built this way.

Recently verified. Verified 22 Aug 2026